Keyphrases
Complete Response
100%
Single Center
100%
MALT Lymphoma
100%
Ultra-low Dose
100%
Definitive Therapy
100%
Response-adapted
100%
Radiotherapy
83%
Stable Disease
33%
Adverse Events
33%
Residual Disease
33%
MD Anderson Cancer Center
16%
Endoscopy
16%
Nausea
16%
Newly Diagnosed
16%
Treatment-related Mortality
16%
Progressive Disease
16%
Partial Response
16%
Stage IV Disease
16%
Follow-up Time
16%
Toxicity Profile
16%
Performance Status
16%
Helicobacter Pylori (H. pylori)
16%
National Cancer Institute
16%
Hispanic
16%
Low Toxicity
16%
Local Relapse
16%
Favorable Prognosis
16%
Treatment Toxicity
16%
Abdominal Pain
16%
Total Dose
16%
Houston
16%
Intention-to-treat
16%
Local Control Rate
16%
Stage I Disease
16%
Distant Relapse
16%
Low-dose Radiotherapy
16%
Lymphoma Therapy
16%
Treatment Performance
16%
Additional Treatment
16%
Exclusion Criteria
16%
External Beam
16%
Medicine and Dentistry
Radiation Therapy
100%
Low Drug Dose
100%
Stomach Mucosa
100%
MALT Lymphoma
100%
Diseases
66%
Malignant Neoplasm
33%
Adverse Event
33%
Minimal Residual Disease
33%
Endoscopy
16%
Progressive Disease
16%
Nausea
16%
Arm
16%
Intention-to-Treat Analysis
16%
Helicobacter Pylori
16%
Abdominal Pain
16%
Immunology and Microbiology
Low Drug Dose
100%
Stomach Mucosa
100%
Mucosa-Associated Lymphoid Tissue
100%
Helicobacter Pylori
33%
Arm
33%